I met Chanel Rion once. She is a charming woman. She is a Harvard Extension School graduate and a tough reporter, the kind who held her ground when she was pushed to the back of the Biden White House briefing room when she was chief White House correspondent for OAN. She now hosts a primetime show ‘Fine Point’ on that network.
She is also a devoted mother of a lovely boy and now, a new little girl, Dior. This week she set the arguments of the day aside and told the country about her baby daughter. It is a hard thing to read, and a harder thing to live.
On Monday evening Chanel wrote that she does not usually get this personal on X. Then she did. Her daughter has a neurodegenerative disorder called TRIT1. Fewer than 30 cases have been documented worldwide.
“We’re living a reality no parent wants to experience,” she wrote. “No parent wants to be told something is terribly wrong with their precious baby. That there is no cure. That she may never walk, talk, or be capable of caring for herself.”
The family’s fundraiser calls her Sweet Baby Dior. Chanel said they learned of the diagnosis in late April or May, when Dior was about four months old and the seizures began. There had been no warning during the pregnancy, and none at her healthy birth. Then came the seizures, an MRI, and the genetic results.
No parent wants to hold a child, she said, and watch doctors shut down her brain and stop her breathing, then revive her, just to break the seizures ravaging her body. “Shutting a part of her down to keep her alive.”
What makes this even harder, Chanel wrote, is that it would be one thing to be told there is nothing to do. It is another to learn that a potential treatment — gene therapy — could help her, but that because the disorder is so rare, no approved treatment exists yet. The technology is there, she said. The world’s top labs and doctors in this space have said yes to helping her baby, and others like her. They cannot do it for free. “The faster we move here the more we can help her. But the window is brutally short.”
The National Institutes of Health’s Genetic and Rare Diseases Information Center describes combined oxidative phosphorylation deficiencies — a group of rare mitochondrial conditions that includes TRIT1 deficiency — as disorders that often begin early in life and can affect the brain and other organs that need a great deal of energy. I will leave the medicine there. I am not a doctor, and this family does not need speculation. They need help.
Chanel is clear about what she hopes this work will become. The technology they are trying to fund, she said, will be given for free to other children born with this disorder. “This isn’t just about funding one child. And this will be her legacy.”
The official campaign is called CURE Trit-1. It is hosted by the Rare Village Foundation, a nonprofit that helps families raise money for rare-disease research. This year’s first essential step, the campaign says, is building a patient-specific mouse model of Dior’s TRIT-1 variant, work led by Dr. Berge Minassian at UT Southwestern, at a cost of about $104,000. Later gifts would support the design and testing of a gene-therapy construct. As of late Tuesday evening, Eastern time, about $66,150 had been raised from roughly 830 donors, toward a goal of $3.42 million. They have a long way to go, and the clock is the part that stays with me.
If you can help, the fundraiser – which is a massive ask, as befits the scope of this problem –is here: https://give.rarevillage.org/campaign/862906/donate
